Do you have stage 1, HER2-positive breast cancer? Has your surgery already been completed? If so, you may be able to take part in a study to help us learn more about a combination of medications to treat your cancer.

Have you been diagnosed with HER-2 positive breast cancer and have already received treatment with chemotherapy followed by surgery? Was your breast cancer still present at time of surgery and removed? If so you may be eligible for a trial to see if a combination of T-DM1 with tucatinib is better than receiving T-DM1 alone at preventing your cancer from returning.

Have you been diagnosed with high-risk early triple-negative breast cancer (TNBC) without mutations in the BRCA1 or BRCA2 gene? If you still have evidence of TNBC in your breast or lymph node tissue after receiving treatment and surgery, you may qualify for this clinical research study. This study will test an experimental drug combination to find out which treatment is better at delaying the return of cancer.